Samyang Biopharm Hits Daily Limit After mRNA Cancer Vaccine Delivery Study Gains Attention
Samyang Biopharm hit the daily price limit on Aug. 20 after announcing that preclinical research on NanoReady, its proprietary delivery platform for therapeutic messenger RNA (mRNA) cancer vaccines, had been published in an international scientific journal.The stock was trading at 56,200 won ($40) a
Samyang Biopharm's stock hit its daily limit on Aug. 20 following the publication of preclinical research on its proprietary mRNA cancer vaccine delivery platform, NanoReady. The stock rose by 29.79% from the previous session, trading at 56,200 won ($40) as of 9:34 a.m. The positive attention was further fueled by Moderna's announcement of positive Phase 3 results for an mRNA-based cancer treatment.
Samyang Biopharm's NanoReady, a nanoparticle-based delivery vehicle, selectively delivers mRNA to dendritic cells in the spleen, which play a crucial role in the immune response. The study, published in the Journal of Controlled Release, demonstrated NanoReady's potential for use in personalized mRNA cancer vaccines, with the added benefit of being able to carry about 20 times more mRNA per particle than conventional lipid nanoparticles.
Brief written by urgent.news from BusinessKorea's own syndicated text. Machine-written — may contain errors; check the original before relying on it.
